- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02435277
An Extension Protocol to Evaluate Dose Comparisons of Leucine-Metformin Combinations in Type 2 Diabetic Patients
An Extension of Protocol NS-0100-01 to Evaluate the Safety and Effect of Various Fixed-Dose Leucine and Metformin Combinations (NS-0100) Versus Standard Metformin Mono-therapy on Glycemic Control in Subjects With Type 2 Diabetes
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
This is a randomized, 8-week, extension of Study NS-0100-01, to evaluate the effect of various fixed-dose (FDC) combinations of leucine and metformin compared to standard metformin monotherapy on glycemic control.
Subjects meeting all inclusion criteria and no exclusion criteria for the extension study, including completion of the 4-week treatment period of Study NS-0100-01 [Day 28/Visit 7]), will be eligible to enroll into the extension. During participation in the extension, subjects will continue to receive their assigned treatment based upon the randomization that occurred on Day 1 (Visit 4) of Study NS-0100-0. The study will include a total of 3 visits: Visit 1E (Day 28/Visit 7 of Study NS-0100-01), Visit 2E (Day 56/Week 8), and Visit 3E (Day 84/Week 12). Key assessments at Visit 2E and Visit 3E include HbA1c, fasting plasma glucose, and plasma insulin. In addition, 3-hour standardized meal tests will be performed on Day 28 (as part of the Study Termination [Visit 7] procedures of Study NS-0100-01 prior to enrolling into the extension) and at Study Termination for the extension (Visit 3E [Day 84/Week 12]).
Study Type
Enrollment (Actual)
Phase
- Phase 2
Contacts and Locations
Study Locations
-
-
California
-
Chino, California, United States, 91710
- Catalina Research Institute
-
-
Florida
-
Palm Beach, Florida, United States, 33409
- Palm Beach Research
-
Tampa, Florida, United States, 33606
- Meridien Research
-
-
Georgia
-
Blue Ridge, Georgia, United States, 3051313
- River Birch Research Alliance
-
Savannah, Georgia, United States, 31406
- Meridian Research
-
-
Ohio
-
Cincinnati, Ohio, United States, 45219
- Streling Research Group
-
-
South Carolina
-
Charleston, South Carolina, United States, 29407
- Medical Research South
-
-
Tennessee
-
Nashville, Tennessee, United States, 37208
- Meharry Medical College
-
Nashville, Tennessee, United States, 37232
- Vanderbilt University Medical Center, Diabetes, Endocrinology, and Metabolism
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Has completed Study NS-0100-01, including all procedures required at Study Termination (Day 28/Visit 7) without major protocol deviations
Is male, or female and, if female, meets all of the following criteria:
- Not breastfeeding
- Post-menopausal or negative pregnancy test result (human chorionic gonadotropin, beta subunit [β-hCG]) at Screening (Visit 1) (not required for hysterectomized females)
- If of childbearing potential (including perimenopausal women who have had a menstrual period within one year) and sexually active, must practice and be willing to continue to practice appropriate birth control (defined as a method which results in a low failure rate, i.e., less than 1% per year, when used consistently and correctly, such as double barrier methods [male condom with spermicide, with or without cervical cap or diaphragm], implants, injectables, oral contraceptives [must have been using for at least the last 3 months], some intrauterine contraceptive devices, tubal ligation, or a vasectomized partner) during the entire duration of the study.
- Is able to read, understand, and sign the informed consent forms (ICF) and if applicable, an authorization to use and disclose protected health information form (consistent with health insurance portability and accountability act of 1996 [HIPAA] legislation), communicate with the investigator, and understand and comply with protocol requirements.
Exclusion Criteria:
Subjects who meet any of the following criteria will be excluded from the study.
- Is undesirable as a study participant as judged by the investigator (e.g., exhibited poor compliance during Study NS-0100-01)
Is expected to require treatment, or if currently on a stable dose, changes to their regimen of the following medications:
- Lipid-lowering agents
- Anti-hypertensive medications
- Thyroid replacement therapy
- Non-steroidal anti-inflammatory agents
Is expected to require or undergo treatment with any of the following medications:
- Antidiabetes medications (with the exception of study medication [i.e., metformin])
- Oral or parenteral steroids.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: RANDOMIZED
- Interventional Model: PARALLEL
- Masking: QUADRUPLE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Low Metformin
3 capsules BID with each capsule containing 366.7 mg L-Leucine and 41.7 mg of metformin
|
1100 mg L Leucine in combination with 125 mg of Metformin BID
Other Names:
|
Experimental: Mid Metformin
3 capsules BID with each capsule containing 366.7 mg L-Leucine and 83.3 mg of metformin
|
1100 mg L Leucine in combination with 250mg Metformin BID
Other Names:
|
Experimental: High Metformin
3 capsules BID with each capsule containing 366.7 mg L-Leucine and 166.7 mg of metformin
|
1100 mg of L Leucine in combination with 500 mg Metformin BID
Other Names:
|
Active Comparator: Metformin Monotherapy
3 Capsules BID each containing 283.3 mg of metformin BID (1,700 mg/Day) at Day 14.
|
500 mg Metformin BID until day 14 with dose escalation at day 14 to 850 mg Metformin BID
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change in HbA1c Levels in Patient Receiving the Various Doses of Leucine and Metformin Combinations
Time Frame: Baseline and 12 weeks
|
Change in HbA1c from Baseline (Day 1/Visit 1) of Study NS-0100-01 to Week 12 (Day 84/Visit 3E) in subjects receiving various fixed-dose combinations of leucine and metformin compared to standard metformin monotherapy.
|
Baseline and 12 weeks
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change in Fasting Plasma Glucose
Time Frame: Baseline and 12 weeks
|
Change in fasting plasma glucose from Baseline (Day 1/Visit 1) of Study NS-0100-01 to Week 12 (Day 84/Visit 3E).
Based on the pre-specified mixed model inferential statistical analysis, there was an apparent dose-dependent relationship for the mean decrease from baseline in fasting plasma glucose for the fixed dose leucine amd metformin combination treatments A, B and C.
|
Baseline and 12 weeks
|
Collaborators and Investigators
Sponsor
Investigators
- Study Chair: Orville Kolterman, MD, Pharmapace
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- NS-0100-01E
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Type 2 Diabetes Mellitus
-
SanofiCompletedType 1 Diabetes Mellitus-Type 2 Diabetes MellitusHungary, Russian Federation, Germany, Poland, Japan, United States, Finland
-
Mannkind CorporationTerminatedType 2 Diabetes Mellitus | Type 1 Diabetes MellitusUnited States
-
RWTH Aachen UniversityBoehringer IngelheimCompletedDiabetes Mellitus Type 2 (T2DM)Germany
-
Griffin HospitalCalifornia Walnut CommissionCompletedDIABETES MELLITUS TYPE 2United States
-
University Hospital Inselspital, BerneCompletedType 2 Diabetes MellitusSwitzerland
-
India Diabetes Research Foundation & Dr. A. Ramachandran...CompletedTYpe 2 Diabetes MellitusIndia
-
Scripps Whittier Diabetes InstituteSan Diego State UniversityCompletedType 2 Diabetes Mellitus (T2DM)United States
-
AstraZenecaRecruiting
-
Daewoong Pharmaceutical Co. LTD.Not yet recruitingT2DM (Type 2 Diabetes Mellitus)
-
Zhongda HospitalRecruitingType 2 Diabetes Mellitus (T2DM)China
Clinical Trials on Low Metformin
-
Hernando GomezNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK); National...Enrolling by invitationSepsis | Septic Shock | Acute Kidney Injury | MetforminUnited States
-
Rutgers UniversityNational Heart, Lung, and Blood Institute (NHLBI)RecruitingMetabolic SyndromeUnited States
-
Jing-yuan Fang, MD, Ph. DRecruitingColorectal Adenoma | Metformin | ChemopreventionChina
-
Garvan Institute of Medical ResearchWeizmann Institute of ScienceActive, not recruitingType 2 Diabetes Mellitus | Pre DiabetesAustralia
-
NuSirt BiopharmaCompletedType 2 Diabetes MellitusUnited States
-
Elaine ChowMerck KGaA, Darmstadt, GermanyNot yet recruiting
-
University of JordanCompletedDiabetes Mellitus, Type 2Jordan
-
Mitsubishi Tanabe Pharma CorporationCompletedType 2 Diabetes MellitusPoland, United Kingdom, Germany, Romania, Hungary, Denmark, Lithuania
-
Caio Eduardo Gonçalves ReisUniversity of Brasilia; Conselho Nacional de Desenvolvimento Científico e Tecnológico and other collaboratorsCompleted
-
Boehringer IngelheimEli Lilly and CompanyCompletedHyperglycemia | Diabetes Mellitus, Type 2United States, Brazil, Canada, Czech Republic, Egypt, France, Germany, Guatemala, Korea, Republic of, Lebanon, Malaysia, Mexico, Peru, Philippines, Russian Federation, Serbia, Spain, Taiwan, Thailand, Turkey, United Kingdom